Skip to main content
Journal cover image

NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis.

Publication ,  Journal Article
Denning, DW; Lee, JY; Hostetler, JS; Pappas, P; Kauffman, CA; Dewsnup, DH; Galgiani, JN; Graybill, JR; Sugar, AM; Catanzaro, A
Published in: Am J Med
August 1994

BACKGROUND: Invasive aspergillosis is the most common invasive mould infection and a major cause of mortality in immunocompromised patients. Response to amphotericin B, the only antifungal agent licensed in the United States for the treatment of aspergillosis, is suboptimal. METHODS: A multicenter open study with strict entry criteria for invasive aspergillosis evaluated oral itraconazole (600 mg/d for 4 days followed by 400 mg/d) in patients with various underlying conditions. Response was based on clinical and radiologic criteria plus microbiology, histopathology, and autopsy data. Responses were categorized as complete, partial, or stable. Failure was categorized as an itraconazole failure or overall failure. RESULTS: Our study population consisted of 76 evaluable patients. Therapy duration varied from 0.3 to 97 weeks (median 46). At the end of treatment, 30 (39%) patients had a complete or partial response, and 3 (4%) had a stable response, and in 20 patients (26%), the protocol therapy was discontinued early (at 0.6 to 54.3 weeks) because of a worsening clinical course or death due to aspergillosis (itraconazole failure). Twenty-three (30%) patients withdrew for other reasons including possible toxicity (7%) and death due to another cause but without resolution of aspergillosis (20%). Itraconazole failure rates varied widely according to site of disease and underlying disease group: 14% for pulmonary and tracheobronchial disease, 50% for sinus disease, 63% for central nervous system disease, and 44% for other sites; 7% in solid organ transplant, 29% in allogeneic bone marrow transplant patients, and 14% in those with prolonged granulocytopenia (median 19 days), 44% in AIDS patients, and 32% in other host groups. The relapse rates among those who completed therapy and those who discontinued early for possible toxicity were 12% and 40%, respectively; all were still immunosuppressed. CONCLUSION: Oral itraconazole is a useful alternative therapy for invasive aspergillosis with response rates apparently comparable to amphotericin B. Relapse in immunocompromised patients may be a problem. Controlled trials are necessary to fully assess the role of itraconazole in the treatment of invasive aspergillosis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Med

DOI

ISSN

0002-9343

Publication Date

August 1994

Volume

97

Issue

2

Start / End Page

135 / 144

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Respiratory Tract Infections
  • Recurrence
  • Organ Transplantation
  • Middle Aged
  • Male
  • Itraconazole
  • Humans
  • General & Internal Medicine
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Denning, D. W., Lee, J. Y., Hostetler, J. S., Pappas, P., Kauffman, C. A., Dewsnup, D. H., … Catanzaro, A. (1994). NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med, 97(2), 135–144. https://doi.org/10.1016/0002-9343(94)90023-x
Denning, D. W., J. Y. Lee, J. S. Hostetler, P. Pappas, C. A. Kauffman, D. H. Dewsnup, J. N. Galgiani, J. R. Graybill, A. M. Sugar, and A. Catanzaro. “NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis.Am J Med 97, no. 2 (August 1994): 135–44. https://doi.org/10.1016/0002-9343(94)90023-x.
Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med. 1994 Aug;97(2):135–44.
Denning, D. W., et al. “NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis.Am J Med, vol. 97, no. 2, Aug. 1994, pp. 135–44. Pubmed, doi:10.1016/0002-9343(94)90023-x.
Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med. 1994 Aug;97(2):135–144.
Journal cover image

Published In

Am J Med

DOI

ISSN

0002-9343

Publication Date

August 1994

Volume

97

Issue

2

Start / End Page

135 / 144

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Respiratory Tract Infections
  • Recurrence
  • Organ Transplantation
  • Middle Aged
  • Male
  • Itraconazole
  • Humans
  • General & Internal Medicine
  • Female